Turatexo 750mcg Injection
Marketer
H & I Critical Care
Salt Composition
Teriparatide (750mcg)
Overview Turatexo 750mcg Injection
Parathyroid hormone replacement therapy, marketed as Turatexo 750mcg Injection, is indicated for the management of severe osteoporosis in men and postmenopausal women at high fracture risk. Its mechanism involves stimulating bone formation, thereby increasing bone mineral density and reducing the likelihood of vertebral fractures. Administration involves subcutaneous injection, either self-administered or by a healthcare provider, maintaining consistent daily timing for optimal efficacy. Treatment typically lasts up to two years, though adherence to the prescribed course is crucial regardless of symptom improvement. Refrigeration between 2°C and 8°C is required for storage. Frequently reported adverse effects include arthralgia, local injection site reactions (pain, edema, erythema), and lower extremity spasms. Persistent or bothersome side effects warrant medical attention. Pre-treatment disclosure of kidney stones or renal dysfunction is vital due to the potential for hypercalcemia. Individuals who are pregnant or lactating should seek medical counsel before commencing treatment. Regular bone density assessments may be recommended to monitor therapeutic progress.
Uses of Turatexo 750mcg Injection
Bone fragility
Major Benefits of Turatexo 750mcg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Turatexo 750mcg Injection:
- Joint pain
- Injection site reactions (pain, swelling, redness)
- Nausea
- Leg cramps
How to use Turatexo 750mcg Injection:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
How Turatexo 750mcg Injection works:
A synthetic analogue of the naturally occurring parathyroid hormone (PTH), Turatexo 750mcg Injection stimulates osteoblast proliferation and activity. This enhanced bone formation leads to stronger bones and a reduced fracture risk.
SAFETY ADVICE
AlcoholCAUTION
Use of Turatexo 750mcg Injection with alcohol requires careful consideration. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Administering Turatexo 750mcg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible adverse effects prior to any prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Data on the use of Turatexo 750mcg Injection while breastfeeding is lacking. Seek medical advice from your physician.
DrivingUNSAFE
The 750mcg Turatexo injection can cause drowsiness, blurred vision, and dizziness, potentially impairing alertness. Driving should be avoided if these effects are experienced.
KidneyCAUTION
Patients with kidney impairment should use Turatexo 750mcg Injection cautiously, potentially requiring a modified dosage. Consult a physician for guidance. Turatexo 750mcg Injection is contraindicated in individuals with severe kidney disease.
LiverCONSULT YOUR DOCTOR
Data on Turatexo 750mcg Injection use in individuals with hepatic impairment is scarce. Physician consultation is advised.
What if you forget to take Turatexo 750mcg Injection :
Should you forget a dose of Turatexo 750mcg Injection, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Turatexo 750mcg Injection
| Label | Value |
|---|---|
| Chemical Type | Parathyroid Hormone-related Drugs |
| Developing Habits | No. |
| Treatment Category | Endocrine Signals |
3,018 People bought this recently